ots Ad hoc-Service: MediGene AG <DE0005020903> MEDIGENE RECEIVES EUROPEAN MARKETING RIGHTS FOR LATE STAGE PROSTATE CANCER DRUG LEUPROGEL(TM)
Martinsried (ots Ad hoc-Service) -
Ad hoc-announcement. The sender is solely responsible for the contents of this announcement.
MEDIGENE RECEIVES EUROPEAN MARKETING RIGHTS FOR LATE STAGE PROSTATE CANCER DRUG LEUPROGEL(TM)
Agreement pushes MediGene closer to commercialization of first drug
The international biopharmaceutical company MediGene AG (NMarkt: MDG) announced today that it has entered into an exclusive European marketing agreement with Atrix Laboratories, Inc. for three products based on Leuprogel(TM) to treat advanced prostate cancer. Atrix Laboratories, Inc. (Nasdaq NM: ATRX) is an emerging specialty pharmaceutical company focused on advanced drug delivery. The clinical trials for the Leuprogel(TM) One Month product have been successfully completed with encouraging results and a new drug application (NDA) has been submitted to the FDA. The phase 3 trials for the three-month and four-month application of Leuprogel(TM) are in progress and Atrix expects to submit an NDA for the Leuprogel Three-Month product later this year (for additional information on Leuprogel(TM) and the clinical trials please refer to the Atrix Laboratories, Inc. Web site at http://www.atrixlabs.com).
Under the terms of the agreement, MediGene will provide all resources needed to conduct clinical research and regulatory activities associated with seeking European marketing approvals. The agreement includes an option for MediGene to develop and market Leuprogel(TM) for additional indications. Atrix will receive license fees and payments for certain clinical, regulatory and sales milestones which could amount to approximately US$ 20 million including the purchase of US$ 4 million in shares of Atrix's common stock. In addition, Atrix will receive royalty payments based on MediGene's sales of the Leuprogel products and will manufacture Leuprogel for MediGene.
For further information please contact:
MediGene AG email: investor@medigene.de fax: ++49 - 89 - 89 56 32-20
Christine Bohner, Public Relations phone: ++49 - 89 - 89 56 32-16 Michael Nettersheim, Investor Relations phone: ++49 - 89 - 89 56 32-46
WKN: 502090; Index: NEMAX- 50 Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart
End Internet: http://recherche.newsaktuell.de
Original-Content von: Medigene AG, übermittelt durch news aktuell